New remarks from U.S. Treasury Secretary Scott Bessent, paired with updated IRS guidance, have signaled regulatory support ...

Roche’s fenebrutinib shows unprecedented positive phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis ...